Axonics Inc
NASDAQ:AXNX
Intrinsic Value
Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunctio... [ Read More ]
The intrinsic value of one AXNX stock under the Base Case scenario is 26.72 USD. Compared to the current market price of 67.13 USD, Axonics Inc is Overvalued by 60%.
Valuation Backtest
Axonics Inc
Run backtest to discover the historical profit from buying and selling AXNX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Balance Sheet Decomposition
Axonics Inc
Current Assets | 482m |
Cash & Short-Term Investments | 332.8m |
Receivables | 50.5m |
Other Current Assets | 98.7m |
Non-Current Assets | 233.5m |
PP&E | 38.9m |
Intangibles | 177m |
Other Non-Current Assets | 17.6m |
Current Liabilities | 48.4m |
Accounts Payable | 15.8m |
Accrued Liabilities | 32.6m |
Non-Current Liabilities | 40.1m |
Other Non-Current Liabilities | 40.1m |
Earnings Waterfall
Axonics Inc
Revenue
|
387.1m
USD
|
Cost of Revenue
|
-95.8m
USD
|
Gross Profit
|
291.3m
USD
|
Operating Expenses
|
-298.8m
USD
|
Operating Income
|
-7.5m
USD
|
Other Expenses
|
-8.5m
USD
|
Net Income
|
-15.9m
USD
|
Free Cash Flow Analysis
Axonics Inc
USD | |
Free Cash Flow | USD |
AXNX Profitability Score
Profitability Due Diligence
Axonics Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Score
Axonics Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
AXNX Solvency Score
Solvency Due Diligence
Axonics Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Score
Axonics Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AXNX Price Targets Summary
Axonics Inc
According to Wall Street analysts, the average 1-year price target for AXNX is 73.16 USD with a low forecast of 71.71 USD and a high forecast of 78.75 USD.
Ownership
AXNX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
AXNX Price
Axonics Inc
Average Annual Return | 21.71% |
Standard Deviation of Annual Returns | 40.13% |
Max Drawdown | -61% |
Market Capitalization | 3.4B USD |
Shares Outstanding | 51 018 500 |
Percentage of Shares Shorted | 7.95% |
AXNX News
Last Important Events
Axonics Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Axonics Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. The company is headquartered in Irvine, California and currently employs 517 full-time employees. The company went IPO on 2018-10-31. The company is engaged in developing and commercializing products for patients with bladder and bowel dysfunction. The bladder and bowel dysfunction includes implantable sacral neuromodulation (SNM) systems to treat urinary urge incontinence (UUI) and urinary urgency frequency (UUF), together referred to as overactive bladder (OAB), as well as fecal incontinence (FI), and non-obstructive urinary retention (UR), and a urethral bulking agent to treat female stress urinary incontinence (SUI). The company has designed and developed the rechargeable sacral neuromodulation (SNM) system (r-SNM System), which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company has two relating to its r-SNM System, a European study, RELAX-OAB, and a United States pivotal study, ARTISAN-SNM. The company offers urethral bulking agent, Bulkamid for stress urinary incontinence.
Contact
IPO
Employees
Officers
The intrinsic value of one AXNX stock under the Base Case scenario is 26.72 USD.
Compared to the current market price of 67.13 USD, Axonics Inc is Overvalued by 60%.